Anagrelide treatment in 52 patients with chronic myeloproliferative diseases

E. Penninga, B. A. Jensen, P. B. Hansen, N. T. Clausen, T. Mourits-Andersen, O. J. Nielsen, H. C. Hasselbalch*

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review


    In this retrospective multi-centre study, we report our experience with anagrelide in the treatment of thrombocytosis in patients with chronic myeloproliferative diseases. Our study included 52 patients (age 20-78 years). The initial anagrelide dose was, in general, 0.5 mg once daily and mean maintenance dosage was 1.7 mg/day. The overall response rate was 79% including 75% complete remission and 4% partial remission. Forty-two patients (81%) had adverse effects and in 29% of the study population, the adverse effects necessitated cessation of anagrelide. The most common adverse effect was moderate anaemia (50%). Two patients experienced erectile dysfunction which has been described only once previously in association with anagrelide treatment. One patient progressed to acute leukaemia. However, this patient had been pre-treated with two potentially leukaemogenic drugs and had only been in short-term treatment with anagrelide. Furthermore, a total of 13 events were recorded. More than 25% of these events occurred in patients with platelet counts between 400 and 600 × 109/l and almost 40% of all events occurred in patients with platelet counts above 400 × 109/l. This observation supports the hypothesis that aggressive control of thrombocytosis to a platelet count <400 × 109/l might reduce the number of thrombohaemorrhagic events. Anagrelide is safe and effective in reducing the platelet counts, but a high proportion of the patients discontinue treatment because of the adverse effects of the drug.

    Sider (fra-til)335-340
    Antal sider6
    TidsskriftClinical and Laboratory Haematology
    Udgave nummer5
    StatusUdgivet - 1 okt. 2004


    Udforsk hvilke forskningsemner 'Anagrelide treatment in 52 patients with chronic myeloproliferative diseases' indeholder.